12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

FDA approved a label expansion for Avastin bevacizumab from Genentech to include second-line treatment in combination with an irinotecan- or oxaliplatin-based chemotherapy regimen in patients with metastatic colorectal cancer (mCRC) who have progressed after first-line treatment with Avastin. The Roche unit said the new indication will...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >